GARFIELD-AF Risk Score

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

حداقل ۳۰ — حداکثر ۳۰۰ • واحد: kg

حداقل ۳۰ — حداکثر ۲۵۰ • واحد: bpm

حداقل ۴۰ — حداکثر ۱۵۰ • واحد: mmHg

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
risk predictions
—percentage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–2
  • Moderate Risk2–5
  • High Risk5–100
Direct Clinical Answer

The GARFIELD-AF Risk Score calculates predicting 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. Key inputs include age. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.

Clinical Indication

The GARFIELD-AF Risk Score is indicated for bedside clinical practice to support The GARFIELD-AF risk score simultaneously predicts 1- and 2-year risks of mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation. This contemporary risk stratification tool incorporates 16 clinical variables and has been validated across diverse international populations with both anticoagulated and non-anticoagulated patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Regular re-evaluation is recommended as clinical status changes may affect risk predictions.

Formula & Variables:

Complex regression model with 16 variables predicting simultaneous risks of mortality, ischemic stroke/systemic embolism, and major bleeding at 1 and 2 years using validated coefficients from GARFIELD-AF registry

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient's age in years(years)
weightfloatYesPatient's body weight(kg)
racestringYesPatient's race/ethnicity
sexstringYesPatient's biological sex
pulseintegerYesHeart rate in beats per minute(bpm)
diastolic_bpintegerYesDiastolic blood pressure(mmHg)
history_of_bleedingstringYesHistory of major bleeding episodes
heart_failurestringYesHistory of heart failure or reduced ejection fraction
history_of_strokestringYesHistory of stroke or transient ischemic attack
chronic_kidney_diseasestringYesChronic kidney disease or renal impairment
vascular_diseasestringYesVascular disease (coronary artery disease, peripheral arterial disease, or aortic plaque)
diabetes_mellitusstringYesDiabetes mellitus requiring medication
current_smokingstringYesCurrent tobacco smoking status
dementiastringYesHistory of dementia or cognitive impairment
antiplatelet_usestringYesCurrent use of antiplatelet medications (aspirin, clopidogrel, etc.)
carotid_diseasestringYesCarotid artery disease or stenosis

Score Interpretation & Guidance

RangeStageDescription
0–2Low RiskLow risk across all outcomes
2–5Moderate RiskModerate risk requiring careful monitoring
5–100High RiskHigh risk requiring intensive management

Evidence-Based References (EBM)

  • Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.DOI: 10.1136/bmjopen-2017-017157
  • Apenteng PN, Murray ET, Holder R, et al. An international longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011.DOI: 10.1016/j.ahj.2011.09.011
  • Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307-314. doi: 10.1136/heartjnl-2016-309832.DOI: 10.1136/heartjnl-2016-309832

Related calculators